| dbo:abstract |
ADB-CHMINACA (also known as MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication. It was identified in cannabinoid blends in Japan in early 2015. (en) |
| dbo:casNumber |
1185887-13-1 |
| dbo:fdaUniiCode |
SL4C60689M |
| dbo:pubchem |
68894304 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/ADB-CHMINACA-fixed.svg?width=300 |
| dbo:wikiPageID |
46992168 (xsd:integer) |
| dbo:wikiPageLength |
8244 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1082421316 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:MDMB-FUBINACA dbr:Pfizer dbc:Cannabinoids dbc:Cyclohexyl_compounds dbc:Designer_drugs dbr:MDMB-CHMICA dbr:MDMB-CHMINACA dbr:5F-AB-PINACA dbr:5F-AMB dbr:5F-ADB dbr:5F-APINACA dbr:AB-CHFUPYCA dbr:AB-CHMINACA dbr:AB-FUBINACA dbr:AB-PINACA dbr:ADB-BINACA dbr:ADB-FUBINACA dbr:ADB-HEXINACA dbr:ADB-PINACA dbr:ADBICA dbr:APICA_(synthetic_cannabinoid_drug) dbr:APINACA dbr:Agonist dbr:Analgesic dbc:Carboxamides dbc:Indazolecarboxamides dbr:PX-3 dbr:List_of_Schedule_I_drugs_(US) dbr:Synthetic_cannabinoid dbr:Indazole dbr:CB1_receptor |
| dbp:c |
21 (xsd:integer) |
| dbp:casNumber |
1185887 (xsd:integer) |
| dbp:chemspiderid |
48059556 (xsd:integer) |
| dbp:h |
30 (xsd:integer) |
| dbp:iupacName |
N-[-1-Amino-3,3-dimethyl-1-oxobutan-2-yl]-1-indazole-3-carboxamide (en) |
| dbp:legalCa |
Schedule II (en) |
| dbp:legalDe |
Anlage II (en) |
| dbp:legalStatus |
Illegal in Singapore, Sweden, Switzerland (en) |
| dbp:legalUk |
Class B (en) |
| dbp:legalUs |
Schedule I (en) |
| dbp:n |
4 (xsd:integer) |
| dbp:o |
2 (xsd:integer) |
| dbp:pubchem |
68894304 (xsd:integer) |
| dbp:smiles |
CC[C@H]C=O (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
ZWCCSIUBHCZKOY-GOSISDBHSA-N (en) |
| dbp:unii |
SL4C60689M (en) |
| dbp:wikiPageUsesTemplate |
dbt:Cannabinoidergics dbt:Cannabinoids dbt:Div_col dbt:Div_col_end dbt:Drugbox dbt:Reflist dbt:Short_description dbt:Cascite dbt:Fdacite |
| dct:subject |
dbc:Cannabinoids dbc:Cyclohexyl_compounds dbc:Designer_drugs dbc:Carboxamides dbc:Indazolecarboxamides |
| gold:hypernym |
dbr:Cannabinoid |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Drug |
| rdfs:comment |
ADB-CHMINACA (also known as MAB-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 0.289 nM and was originally developed by Pfizer in 2009 as an analgesic medication. It was identified in cannabinoid blends in Japan in early 2015. (en) |
| rdfs:label |
ADB-CHMINACA (en) |
| owl:sameAs |
freebase:ADB-CHMINACA yago-res:ADB-CHMINACA wikidata:ADB-CHMINACA https://global.dbpedia.org/id/xvcB |
| prov:wasDerivedFrom |
wikipedia-en:ADB-CHMINACA?oldid=1082421316&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/ADB-CHMINACA-fixed.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:ADB-CHMINACA |
| is dbo:wikiPageRedirects of |
dbr:C21H30N4O2 dbr:MAB-CHMINACA |
| is dbo:wikiPageWikiLink of |
dbr:List_of_designer_drugs dbr:MDMB-FUBINACA dbr:List_of_psychedelic_drugs dbr:NE-CHMIMO dbr:MDMB-CHMICA dbr:MDMB-CHMINACA dbr:MDMB-FUBICA dbr:5F-AB-PINACA dbr:5F-ADB-PINACA dbr:5F-AMB dbr:C21H30N4O2 dbr:Drugs_controlled_by_the_German_Betäubungsmittelgesetz dbr:5F-ADB dbr:5F-APINACA dbr:5F-EMB-PINACA dbr:AB-CHFUPYCA dbr:AB-CHMINACA dbr:AB-FUBINACA dbr:AB-PICA dbr:AB-PINACA dbr:ADB-4en-PINACA dbr:ADB-BINACA dbr:ADB-FUBINACA dbr:ADB-HEXINACA dbr:ADB-PINACA dbr:ADBICA dbr:AMB-FUBINACA dbr:APICA_(synthetic_cannabinoid_drug) dbr:APINACA dbr:APP-FUBINACA dbr:Adamantyl-THPINACA dbr:FUB-APINACA dbr:PX-1 dbr:PX-2 dbr:PX-3 dbr:List_of_Schedule_I_drugs_(US) dbr:AMB-CHMINACA dbr:MA-CHMINACA dbr:MAB-CHMINACA |
| is foaf:primaryTopic of |
wikipedia-en:ADB-CHMINACA |
